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doi:10.1016/j.kjms.2010.09.001Abstract The Philadelphia (Ph) chromosome and/or Breakpoint cluster region-Abelson
leukemia virus oncogene transcript are unique markers for chronic myeloid leukemia (CML).
However, CML demonstrates heterogeneous presentations and outcomes. We analyzed the cyto-
genetic and molecular results of CML patients to evaluate their correlation with clinical presen-
tations and outcome. A total of 84 newly diagnosed CML patients were enrolled in the study.
Patients were treated according to disease status. Bone marrow samples were obtained to
perform cytogenetic and molecular studies. Clinical presentations, treatment courses, and
survival were reviewed retrospectively. Among 84 patients, 72 had chronic phase and 12 had
accelerated phase CML. Cytogenetic study showed 69 (82.1%) with the classic Ph chromosome,
6 (7.2%)with a variant Ph chromosome, and 9 (10.7%)with additional chromosomeabnormalities.
Fifty-four (64.3%) cases harbored b3a2 transcripts, 29 (34.5%) had b2a2 transcript, and 1 had
e19a2 transcript. There was no difference in clinical presentations between different cytoge-
netic and molecular groups; however, additional chromosome abnormalities were significantly
associated with the accelerated phase. Imatinib therapy was an effective treatment, as
measured by cytogenetic response, when administered as first- and second-line therapy in
chronic phase patients. Survival analysis showed that old age, additional chromosome abnormal-
ities, high Sokal score, and no cytogenetic response in second-line therapy had a significant poor
impact (p< 0.05). In conclusion, we presented the cytogenetic and molecular pattern of CML
patients and demonstrated that the additional chromosome abnormality was associated with
poor outcome.ematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100
aiwan.
.tw (S.-F. Lin).
vier Taiwan LLC. All rights reserved.
50 H.-H. Hsiao et al.摘要 慢性骨髓性白血病通常帶有獨特的標記，包括費城染色體和BCR-ABL的基因，然而此病之
臨床表現及預後卻往往有很大的差異。因此我們分析慢性骨髓性白血病病患之染色體及基因檢查
之結果，來看是否這些資料和臨床表現及預後有相關。共有84位新診斷的慢性骨髓性白血病病人
進行分析，而這些病人的治療是依據病患的狀況予以治療。染色體及基因檢查是由病患的骨髓檢
體所做之檢查，而病患的臨床表現、治療狀況及預後是由病歷資料回顧所得。於84位病人中有72
位是屬於慢性期，有12位是屬於加速期。染色體檢查中有69位 (82.1%)是屬於標準的費城染色
體，有6位 (7.2%)是屬於變異的費城染色體，有9位 (10.7%) 是屬於額外染色體變化。基因檢查中
有54位(64.3%)是屬於b3a2，有29位(34.5%)是屬於b2a2，有1位是屬於e19a2。病患的臨床表現和
不同組的染色體及基因並無差別，但是額外染色體變化卻和病患的加速期有相關。而Imatinib對
慢性期病患於一線及二線的治療均有不錯之反應。生存分析中發現年紀愈大、有額外染色體變
化、有較高的Sokal分數、對二線的治療反應不佳者有有意義的負面影響(p<0.05)。我們於此報告
中顯示了慢性骨髓性白血病病患之染色體及基因變化，且顯示出額外染色體變化對慢性骨髓性白
血病有不良之影響。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Chronic myeloid leukemia (CML) is characterized by the
presence of Philadelphia (Ph) chromosome, a result of
a balanced translocation between chromosomes 9 and 22,
that is, t(9;22)(q34;q11) [1,2]. The translocation results in
the formation of the chimeric oncogene, Breakpoint cluster
region-Abelson leukemia virus oncogene (BCR-ABL),
encoding the protein p210BCR-ABL [3e5]. Despite the pres-
ence of unique cytogenetic and molecular hallmarks, CML
demonstrates heterogeneous clinical presentations and
outcomes [6]. Patients show variable survival from several
years to decades and also respond differently to the
medications. In addition, the heterogeneous characteristics
of CML are also apparent at cytogenetic and molecular
levels [6,7]. Most CML patients harbor the classic Ph;
however, 5%e10% of patients have variant translocations in
which at least a third chromosome is involved in the rear-
rangement [8e10]. Additionally, depending on the different
breakpoints of the BCR gene, most CML cases harbor
a fusion oncogene comprising either the b3a2 or b2a2
transcripts [4,11].
Although some studies demonstrated that the diversities
in cytogenetic and molecular levels might explain the
heterogeneities of CML patients in some respects, the
results are still equivocal [6,12e15]. In this study, newly
diagnosed CML patients in our hospital were analyzed to see
whether diversity at the cytogenetic and molecular levels
was correlated with clinical features and outcome.
Materials and methods
Patients
From January 2001 to January 2010, a total of 84 newly diag-
nosedCMLpatientsweretreated inourhospital andenrolled in
the study. The diagnosis of CMLwas established on the basis of
bone marrow examination, supported by cytogenetic,
molecular studies, and lowperipheralblood leukocytealkaline
phosphatase activity. The disease status was classified into
chronic phase (CP) and accelerated phase (AP), defined as the
presence of at least 15% blasts, 30% blasts plus promyelocytes
in the blood or marrow, at least 20% peripheral basophils, orthrombocytopenia unrelated to treatment [16]. Patients were
treated according to the status of the disease with cytotoxic
agents, including hydroxyurea, interferon-alpha, cytarabine,
imatinib mesylate, and/or allogeneic stem cell transplant
(SCT). Cytogenetic response (CgR) was defined as 0%e35% of
cells with Ph chromosome in the follow-up examination.
Clinical presentations, treatment courses, and survival dura-
tion were reviewed from the medical records retrospectively.
Cytogenetic study
Cytogenetic studies were obtained from bone marrow
samples of the patients at the time of diagnosis. The study
was performed from unstimulated specimens by Giemsa-
banding method. The results were identified according to
the Human System for Cytogenetic Nomenclature.
Molecular study
BCR-ABL transcript was detected by standard reverse tran-
scriptase polymerase chain reaction (RT-PCR) [17]. Briefly,
RNA was extracted from Ficoll-separated mononuclear cells
fromthebonemarrowspecimens.RT-PCRwasperformedwith
standard technique. The resulting fragments were separated
and identified by 3% gel electrophoresis and visualized by
ethidiumbromide stain. Different types of the transcriptwere
identified from the electrophoresis as reported.
Statistical analysis
The results were analyzed by SPSS version 11.5 (SPSS Inc.,
Chicago, IL, USA) for Windows. Chi-squared test was used to
test the categorical variables. Continuing variables were
compared by the t-test. The Kaplan-Meier method was used
for survival analysis and the differences between each group
were compared by the Long-rank test. All living patientswere
censored in January 2010 or at the date of last visit. A p value
of less than 0.05 was considered as statistically significant.
Results
A total of 84CMLpatientswereenrolled in the study, including
51males and 33 females (Table 1). Twelve cases (14.3%) were
Table 1 Clinical features of the patients (nZ 84)a
Male/female 51/33 (60.7%/39.3%)
Age, yr 41.8 (13e81)
White cell count (109/L) 138,789 (11,400e968,000)
Hemoglobin (g/dL) 10.1 (6.5e14.2)
Platelet count (109/L) 409,158 (87,000e2,509,000)
Phase
Accelerating phase 12 (14.3%)
Chronic phase 72 (85.7%)
Cytogenetics
Classical 69 (82.1%) (7 AP)
Variant 6 (7.2%) (1 AP)
Additional 9 (10.7%) (4 AP)
Molecular
b3a2 54 (64.3%)
b2a2 29 (34.5%)
e19a2 1 (1.2%)
Treatment
Chronic phase (nZ 72)
First-line therapy
Cytotoxic agents 42 No CgR (3 expired)
Imatinib 30 29 CgR (1 expired because of car accident)
Second-line therapy
Imatinib 22 16 CgR (4 expired)
SCT 18 16 CgR (1 expired)
Accelerating phase (nZ 12)
First-line therapy
Imatinibþ cytotoxic agents 9 3 CgR (2 expired)
Cytotoxic only 3 No CgR (2 expired)
a Data presented as mean (range) or n (%).
APZ accelerated phase; CgRZ cytogenetic response; CPZ chronic phase; SCTZ stem cell transplant.
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Forty-two CP patients received cytotoxic agents as the first-
line treatment resulting in no CgR and 3 mortalities; whereas
29ofother 30CPpatientswith imatinib therapyachievedCgR.
Forty patients, 39 from cytotoxic group and 1 from the ima-
tinib group, received second-line therapy with imatinib (22
patients) and SCT (18 patients). Sixteenof the 22patientswho
had imatinib as second-line therapy achievedCgR,whereas 16
of the 18 SCT patients had CgR. Among 12 AP patients, 3 had
cytotoxic agents without a CgR. Other nine patients with
imatinib plus cytotoxic agents as first-line therapy showed
three CgR in the follow-up.
Cytogenetic and molecular results
All patients were positive for BCR-ABL transcripts, 54 cases
(64.3%) harbored b3a2 transcripts, whereas 29 cases (34.5%)
hadb2a2 transcript and1 casehade19a2 transcript (Table 1).
The different molecular type had no significant difference in
gender, age, white cell count, hemoglobin level and platelet
count, cytogenetic subtype and disease status.
In these patients, 69 (82.1%) cases showed classical Ph
chromosomes, whereas 6 patients (7.1%) had variant Phchromosome and other 9 (10.7%) patients harbored additional
chromosome abnormalities at the time of diagnosis (Tables 1
and 2). Four out of nine patients in additional group were in
AP at the diagnosis. Compared with classical Ph group,
patients with additional chromosome abnormalities were
associated with AP significantly (7/69 in classical Ph group vs.
4/9 in additional group; pZ 0.023) and have a trend of
transformation from CP to AP (pZ 0.096). Among six cases
with variant Ph, only one case showed AP in the diagnosis.
There was no difference in gender, age, white cell count,
hemoglobin level, platelet count, disease status and survival
between variant, additional and classical groups.
Outcomes
With a mean follow-up of 40.8 months, 13 mortalities were
noted, including 1 car accident (Table 1). Patients in AP
were significantly associated with poor survival
(pZ 0.0137), whereas therapy with imatinib showed
a borderline benefit (pZ 0.0541) in these patients. In CP
patients, old age, additional chromosome abnormality, high
Sokal score, and no CgR in second-line therapy had poor
impact on survival significantly by univariable analysis
Table 2 Characters of nonclassic Philadelphia chromosomes
No Chromosome result Disease
status
First-line
therapy
Second-line
therapy
Survival (mo)
Variant Philadelphia chromosome
1 46,XY,t(3;22)(p24;q11)[8] CP Cy SCT 99
2 46,XY,t(9;9;22)(p13;q34;q11)[20] CP Cy SCT 46
3 46,XY,t(9;22;12)(q34;q11;q13)[20] CP Cy SCT 44
4 46,XX,t(9;22;15)(q34;q11;q24)[20] CP Cy SCT 45
5 46,XY,t(9;22;14)(q34;q11;q23)[20] CP Cy Imatinib 18
6 46,XY,t(4;9;22)(q21;q34;q11)[19] AP Imatinib - 20
Additional chromosome abnormalities
7 46,XY,t(9;22)(q34;q11),ins(19)(q13.3:q13.4)[14] CP Cy Imatinib 44a
8 47,XY,t(9;22)(q34;q11),þPh[17]/48,XY, idem,þ8[3] CP Cy Imatinib 40a
9 46,XX,t(9;22)(q34;q11)[5]/46,XX,idem,der(1)(q?)[10] AP Cy - 10a
10 47,XY,t(9;22)(q34;q11),þPh[5]/45-47, XY,idem,-17[15] AP Cy - 16a
11 46,XY,t(9;22)(q34;q11),t(2;3)(p25;p21)[10] CP Cy Imatinib 63
12 46,XY,t(9;22)(q34;q11)[15]/47,XY,idem,þPh[5] CP Cy SCT 58
13 46,XY,t(2;12)(p11;p11),t(3;5)(q12;p15),t(9;22)(q34;q11)[5] CP Cy 36a
14 46,XY,t(9;22)(q34;q11)[17]/46,XY,idem,t(2;21)[3] AP Imatinibþ Cy - 23a
15 46,XY,t(9;22)(q34;q11)[11]/46,XY,idem,þPh,-7[9] AP Imatinib - 26
a Patient died.
APZ accelerated phase; CPZ chronic phase; CyZ cytotoxic agents; SCTZ stem cell transplant.
52 H.-H. Hsiao et al.(Table 3). However, none of them reached a statistically
significant difference on survival by the multivariable
analysis. Compared with cytotoxic therapy, imatinib
therapy showed a significant higher CgR (pZ 0.028) as the
first-line therapy in CP patients and the response of ima-
tinib was higher in the first-line than second-line therapy
(93.1% vs. 72.7%; pZ 0.048).
Discussion
Although most CML patients harbor unique hallmarks, such
as the Ph chromosome and/or the BCR-ABL fusion transcript
[1e6], they demonstrate heterogeneous characteristics in
clinical presentations and outcomes [6,7]. Some studies
showed that the heterogeneity might contribute with
the diversity at the molecular and cytogenetic levels, butTable 3 Statistic result of patients in chronic phase
(nZ 72)
Characters p
Age (>60 yr) 0.0483a
Gender 0.8335
WBC (>100,000 109/L) 0.6587
Platelet count (>500,000 109/L) 0.4309
Anemia (Hg<12 g/dL) 0.5930
Additional chromosome 0.0070a
Molecular type (b3a2 vs. b2a2) 0.0713
First-line therapy (imatinib vs. cytotoxic agents) 0.5688
CgR in first-line therapy 0.1658
Second-line therapy (imatinib vs. SCT) 0.2009
CgR in second-line therapy 0.0010a
High Sokal risk 0.0291a
a Significant difference with p< 0.05.
CgRZ cytogenetic response; SCTZ stem cell transplant.other reports did not concur with it [6,12e15]. In our study,
we report the clinical presentations of CML and showed
that the additional chromosome abnormalities at diagnosis
are associated with poor outcomes and a high frequency
in AP.
The prognostic impact of clonal evolution in CML patients
during follow-up is well established, which is highly associ-
atedwith diseaseprogression [9,18e20]. In contrast, the role
of additional chromosome abnormality at diagnosis is still
uncertain [21,22]. However, the fact that many patients
(four of nine) with additional abnormality were at AP at
diagnosis and three of the other five patients suffered from
transformation to AP in the follow-up suggested that the
additional chromosome was associated with the advanced
status of CML [19,23]. Furthermore, our study also demon-
strated that additional chromosome abnormalities had
a significant impact on survival in CP patients. It concurred
with previous reports and implied that additional chromo-
some abnormalities at diagnosis should be taken into
consideration in the outcome of CML [22,24e28].
Some reports suggested that patients with variant Ph
chromosomes might have a worse outcome, especially when
the 50-ABL region was deleted [7,29e31]. However, our data
did not support this result. It might come from the fact
that four of these six patients underwent SCT later, which
might have some positive effect on the prognosis [32,33]. Our
data also could not identify any significant differences in the
white cell count, hemoglobin level, platelet count, disease
status, and survival between different types of BCR-ABL
transcript.
Although this is a retrospective study, our data demon-
strated that imatinib is an effective therapy with a high
response rate in both first- and second-line therapy [16].
The late CP after initial first-line treatment might
contribute to the inferior response of imatinib in second-
line therapy [22]. Our results also showed that CgR in
Additional chromosome abnormality in CML 53second-line therapy had a survival benefit in CP patients.
This might result from patients having an effective salvage
therapy, with either imatinib or SCT, after first-line
therapy. The survival benefit of imatinib compared with
SCT is still unclear [32e34]. Our limited data also could not
identify the survival difference.
In summary, we presented the clinical presentations,
cytogenetic results, molecular data, and outcomes of 84 CML
patients. The distribution of cytogenetic and molecular
results was similar to that in other populations and there was
no difference in clinical presentations between different
cytogenetic and molecular groups. However, additional
chromosome abnormality at diagnosis was associated with
poor outcome because of high frequency in AP patients and
a worse survival in CP patients, whereas variant Ph chro-
mosome had no impact on the clinical presentations and
outcomes. Imatinib therapy was an effective treatment with
a high response rate in either first- or second-line therapy.
However, further prospective studies about the role of
additional chromosome in the era of imatinib are warranted
to draw more obvious conclusions.
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